CD28 and prostate carcinoma: NK-92 cells expressing a first-generation EpCAM-specific CAR or coexpressing IL-15 and a second-generation EpCAM-specific CAR with intracellular signaling domains of CD28 were also developed to treat prostate cancer in mouse models [45, 46].